Sunitinib
Sunitinib is a small-molecule tyrosine kinase inhibitor used as an anticancer therapy, best known for its anti-angiogenic and antiproliferative activity.
Sunitinib is a small-molecule tyrosine kinase inhibitor used as an anticancer therapy, best known for its anti-angiogenic and antiproliferative activity. It targets multiple receptor tyrosine kinases involved in tumor growth and vascular signaling, including VEGFR-2, and is widely used as a comparator or backbone therapy in renal cell carcinoma and other solid tumors. By inhibiting signaling pathways that support angiogenesis and tumor cell survival, sunitinib can slow disease progression in settings where vascular growth and kinase-driven proliferation are central features.
In biomedical research, sunitinib is frequently used as a reference treatment for advanced renal cell carcinoma and as a benchmark for newer combinations such as axitinib-based regimens, checkpoint inhibitor, and other targeted approaches. Recent studies also continue to examine mechanisms of resistance to sunitinib, including metabolic and cell-death pathways such as cuproptosis and ferroptosis, as well as its potential role in combination strategies with radiotherapy or chemotherapy.
Where the papers sit
10 papers from the last 6 months study sunitinib directly · updated from PubMed 12 Nov 2026
Study type 0 clinical trials · 2 human data · 8 preclinical
Themes 3 themes
-
Nanomedicine for Tumor Therapy
Nanoparticle and hydrogel strategies are being used to improve tumor-localized therapy and sunitinib release. pH-responsive systems, antibody targeting, and sustained delivery seek greater intratumoral exposure with less systemic toxicity. Distribution studies connect drug localization with responses in primary and metastatic tumors. Photothermal ablation broadens the field beyond kinase inhibition toward combined or alternative physical tumor destruction.
4 papers · 40%
-
Sunitinib in Renal Cancer
Renal cancer treatment is moving toward combinations that pair kinase inhibition with immune activation or cuproptosis. Avelumab plus axitinib, and hydrogel-delivered sunitinib with immune reprogramming, represent this combination-focused direction. LGALS1-driven fatty-acid metabolism provides a mechanism for clear cell renal cell carcinoma resistance. Fluorescent sunitinib detection supports treatment monitoring, but its clinical role remains separate from the resistance studies.
4 papers · 40%
-
Others — Sunitinib Toxicity and Resistance
Cardiotoxicity and tumor resistance emerge as separate problems in sunitinib treatment. Cardiac studies focus on calcium-handling pathways and population heterogeneity, including tocotrienol-related protection. Hepatocellular carcinoma resistance is linked to PYCR2 and PPAR signaling. The cluster lacks a single disease or mechanism connecting these findings.
2 papers · 20%
Papers
The 10 papers from the last 6 months that study sunitinib directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Nanomedicine for Tumor Therapy (4)
- Converting lysosomes into photothermal organelles enables nanoparticle-free tumor ablation via intracellular vapor bubbles. Science advances · 25 Sept 2026 PMID 42789725
- Boswellic Acid-Integrated Chitosan Hybrid Nanogels for pH-Responsive Sustained Sunitinib Release and Lung Tumor Suppression. ACS applied materials & interfaces · 9 Sept 2026 PMID 42713680
- Comparative assessment of intratumoral sunitinib distribution and therapeutic response in matched primary and metastatic tumor models. European journal of pharmacology · 22 Aug 2026 PMID 42632509
- Anti-carcinoembryonic antigen conjugated resveratrol/sunitinib-loaded polymeric nanoparticles for therapeutic enhancement in colorectal cancer. International journal of biological macromolecules · 14 Jul 2026 PMID 42448198
Sunitinib in Renal Cancer (4)
- A Signal-Switchable Fluorescent-Colorimetric Dual-Signal Probe for Detection of Sunitinib Based on D-Penicillamine-Functionalized Silicon Nanoparticles. Luminescence : the journal of biological and chemical luminescence · 30 Oct 2026 PMID 42958717
- Injectable pH-responsive gelatin methacryloyl hydrogel for cuproptosis-synergized sunitinib therapy and immune reprogramming in clear cell renal cell carcinoma. Acta biomaterialia · 2 Jul 2026 PMID 42392517
- LGALS1 promotes the malignant progression and sunitinib resistance of clear cell renal cell carcinoma by reprogramming fatty acid metabolism. International immunopharmacology · 20 Jun 2026 PMID 42322858
- Bayesian Evaluation of Treatment Effect of Avelumab Plus Axitinib for Advanced Renal Cell Carcinoma. Cancer medicine · 30 May 2026 PMID 42216439
Others — Sunitinib Toxicity and Resistance (2)
- PMID 42155340
- Cell Village Captures Populational Heterogeneity of Sunitinib Cardiotoxicity. Circulation research · 9 Oct 2026 PMID 42852499
By study type
Human data, design not indexed (2)
- Cell Village Captures Populational Heterogeneity of Sunitinib Cardiotoxicity. Circulation research · 9 Oct 2026 PMID 42852499
- Bayesian Evaluation of Treatment Effect of Avelumab Plus Axitinib for Advanced Renal Cell Carcinoma. Cancer medicine · 30 May 2026 PMID 42216439
Preclinical: animal, cell and lab studies (8)
- A Signal-Switchable Fluorescent-Colorimetric Dual-Signal Probe for Detection of Sunitinib Based on D-Penicillamine-Functionalized Silicon Nanoparticles. Luminescence : the journal of biological and chemical luminescence · 30 Oct 2026 PMID 42958717
- Construction of pH-Sensitive Dynamic Composite Hydrogels and Their Local Targeted Antitumor Research. ACS applied bio materials · 27 Oct 2026 PMID 42945386
- Converting lysosomes into photothermal organelles enables nanoparticle-free tumor ablation via intracellular vapor bubbles. Science advances · 25 Sept 2026 PMID 42789725
- Boswellic Acid-Integrated Chitosan Hybrid Nanogels for pH-Responsive Sustained Sunitinib Release and Lung Tumor Suppression. ACS applied materials & interfaces · 9 Sept 2026 PMID 42713680
- Comparative assessment of intratumoral sunitinib distribution and therapeutic response in matched primary and metastatic tumor models. European journal of pharmacology · 22 Aug 2026 PMID 42632509
- Anti-carcinoembryonic antigen conjugated resveratrol/sunitinib-loaded polymeric nanoparticles for therapeutic enhancement in colorectal cancer. International journal of biological macromolecules · 14 Jul 2026 PMID 42448198
- Injectable pH-responsive gelatin methacryloyl hydrogel for cuproptosis-synergized sunitinib therapy and immune reprogramming in clear cell renal cell carcinoma. Acta biomaterialia · 2 Jul 2026 PMID 42392517
- LGALS1 promotes the malignant progression and sunitinib resistance of clear cell renal cell carcinoma by reprogramming fatty acid metabolism. International immunopharmacology · 20 Jun 2026 PMID 42322858
Written from 10 PubMed abstracts, each one listed by PMID above. Published: 2026-06-16. Last written: 2026-08-27 by GPT. Drafted by language models from published abstracts; not medical advice.